Biological products
Definition
SIC 2836, biological products other than diagnostics.
A standard grouping: SIC 2836.
Q2 2026 against Q1 2026
- Reported value
- $145bn
- +$21.6bn on the quarter before
- Managers listing any
- 61
- +0 on the quarter before
- Stocks listed
- 82
- +0 on the quarter before
- Buyers
- 1,034
- manager-stock pairs opening or adding
- Sellers
- 890
- manager-stock pairs trimming or exiting
value over 8 quartersNet buying actions by quarter: +70 · +53 · +58 · +41 · +35 · +218 · +184 · +144
See it in the heatmap, ranked by breadth →
Managers listing any counts distinct comparable managers. Buyers and sellers count actions by comparable managers, once for each stock a manager moved in. Value moves with prices as well as with buying.
Largest stocks (85 in all)
By combined reported value at Q2 2026. Holders are at least counts, among listed positions.
| Stock | Holders | Value | Buyers | Sellers | Holders, 8 quarters |
|---|---|---|---|---|---|
| GILDGilead Sciences Inc | 37 | $34.6bn | 22 | 16 | |
| AMGNAmgen Inc | 31 | $25.2bn | 19 | 13 | |
| ARGXArgenx Se | 29 | $15.4bn | 16 | 15 | |
| RVMDRevolution Medicines Inc | 31 | $10.7bn | 16 | 23 | |
| MRNAModerna Inc | 27 | $8.1bn | 17 | 17 | |
| BIIBBiogen Inc | 29 | $6.2bn | 16 | 17 | |
| EXELExelixis Inc | 34 | $3.6bn | 22 | 10 | |
| PCVXVaxcyte Inc | 25 | $3.2bn | 13 | 17 | |
| KYMRKymera Therapeutics Inc | 22 | $3.2bn | 12 | 13 | |
| NBIXNeurocrine Biosciences Inc | 28 | $3.1bn | 16 | 16 | |
| TECHBio-techne Corp | 40 | $2.9bn | 24 | 18 | |
| TWSTTwist Bioscience Corp | 29 | $2.8bn | 17 | 15 | |
| KRYSKrystal Biotech Inc | 20 | $2.6bn | 12 | 14 | |
| SRRKScholar Rock HLDG Corp | 25 | $2.4bn | 14 | 15 | |
| RGENRepligen Corp | 27 | $1.9bn | 19 | 10 | |
| QGENQiagen NV | 29 | $1.5bn | 19 | 15 | |
| BNTXBiontech Se | 23 | $1.5bn | 15 | 10 | |
| BEAMBeam Therapeutics Inc | 24 | $1.4bn | 17 | 8 | |
| ADPTAdaptive Biotechnologies Corp | 29 | $1.3bn | 12 | 20 | |
| HALOHalozyme Therapeutics Inc | 32 | $1.2bn | 17 | 16 | |
| IMVTImmunovant Inc | 21 | $1.2bn | 15 | 8 | |
| CRSPCrispr Therapeutics AG | 24 | $1.2bn | 15 | 8 | |
| CGONCG Oncology Inc | 18 | $1.1bn | 12 | 12 | |
| DNLIDenali Therapeutics Inc | 23 | $857m | 13 | 12 | |
| RLAYRelay Therapeutics Inc | 23 | $719m | 14 | 13 |
Managers holding its largest names
Across the 15 largest stocks above at Q2 2026: how many of them each manager lists, and their combined value. A manager can hold others below its listed range.
- Fidelity (FMR LLC)11 of 15 · $30.6bn
- Capital World Investors7 of 15 · $20.4bn
- Invesco Ltd6 of 15 · $12.5bn
- T. Rowe Price Associates Inc10 of 15 · $10.6bn
- Janus Henderson Group Ltd10 of 15 · $6.6bn
- Wellington Management Group LLP9 of 15 · $6.2bn
- Capital Research Global Investors6 of 15 · $5.2bn
- Dodge & Cox3 of 15 · $3.9bn
- Farallon Capital Management LLC4 of 15 · $3.5bn
- MFS Investment Management6 of 15 · $2.0bn
- Artisan Partners LP3 of 15 · $1.9bn
- AQR Capital Management LLC4 of 15 · $1.9bn
- Two Sigma Investments LP6 of 15 · $1.8bn
- Baillie Gifford & Co4 of 15 · $1.4bn
- AllianceBernstein LP6 of 15 · $1.4bn
- Renaissance Technologies LLC3 of 15 · $1.4bn
- D. E. Shaw & Co.5 of 15 · $1.3bn
- Holocene Advisors LP5 of 15 · $1.0bn
- Woodline Partners LP12 of 15 · $876m
- Citadel Advisors LLC2 of 15 · $695m